Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial

The Lancet Global Health

Volumn 4, Issue 12, 2016, Pages e955-e965

  Victor, John C ^a   Lewis, Kristen D C ^a   Diallo, Aldiouma ^b   Niang, Mbayame N ^c   Diarra, Bou ^b   Dia, Ndongo ^c   Ortiz, Justin R ^a,d   Widdowson, Marc Alain ^e   Feser, Jodi ^a   Hoagland, Rebecca ^f   Emery, Shannon L ^e   Lafond, Kathryn E ^e   Neuzil, Kathleen M ^g  

^a PATH   (United States)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c Institut Pasteur de Dakar   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^f Cota Enterprises Inc ^*  (United States)

^g University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PLACEBO; LIVE VACCINE;

ANASARCA; ARTICLE; CHILD; CHILL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; INFLUENZA; INFLUENZA VACCINATION; MALE; MALNUTRITION; MYALGIA; NOSE OBSTRUCTION; OTALGIA; OUTCOME ASSESSMENT; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RHINORRHEA; SENEGAL; SORE THROAT; TACHYPNEA; VOMITING; WHEEZING; INFANT; INTRANASAL DRUG ADMINISTRATION; PROCEDURES; VACCINATION;

ADMINISTRATION, INTRANASAL; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; SENEGAL; VACCINATION; VACCINES, ATTENUATED;

EID: 84991266847     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(16)30201-7     Document Type: Article

References (39)

1. 1 Liu, L, Johnson, HL, Cousens, S, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 379 (2012), 2151–2161.
2. 2 GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385 (2015), 117–171.
3. 3 Nair, H, Simoes, EAF, Rudan, I, et al. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet 381 (2013), 1380–1390.
4. 4 Nair, H, Brooks, WA, Katz, M, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 378 (2011), 1917–1930.
5. 5 Ambrose, CS, Levin, MJ, Belshe, RB, The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influ Other Respir Viruses 5 (2011), 67–75.
6. 6 Belshe, RB, Toback, SL, Yi, T, Ambrose, CS, Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influ Other Respir Viruses 4 (2010), 141–145.
7. 7 Neuzil, KM, Tsvetnitsky, V, Nyari, LJ, Bright, RA, Boslego, JW, PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries. Expert Rev Vaccines 11 (2012), 939–947.
8. 8 Block, SL, Toback, SL, Yi, T, Ambrose, CS, Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: a post hoc analysis of three studies of children aged 2 to 6 years. Clin Ther 31 (2009), 2140–2147.
9. 9 Niang, MN, Dosseh, A, Ndiaye, K, et al. Sentinel surveillance for influenza in Senegal, 1996-2009. J Infect Dis 206 (2012), S129–S135.
10. 10 Friede, M, Palkonyay, L, Alfonso, C, et al. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine 29 (2011), A2–A7.
11. 11 WHO. Child Growth Standards: WHO Anthro (version 3.2.2, January 2011) and macros. http://www.who.int/childgrowth/software/en/, 2011 (accessed Sept 10, 2015).
12. 12 WHO. Growth reference 5–19 years: Application Tools. http://www.who.int/growthref/tools/en/, 2015 (accessed Sept 10, 2015).
13. 13 Brooks, WA, Zaman, K, Lewis, KDC, et al. Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial. Lancet Glob Health, 2016 published online Oct 13. http://dx.doi.org/10.1016/S2214-109X(16)30200-5.
14. 14 Breiman, RF, Brooks, WA, Goswami, D, et al. A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children. Vaccine 27 (2009), 5472–5479.
15. 15 Corey, J, Sahin-Yilmaz, A, Assessment of nasal function. Snow, J, Wackym, P, (eds.) Ballenger's otorhinolaryngology head and neck surgery, 2009, People's Medical Publishing House, BC Decker Inc, Shelton, Conn; Hamilton, ON, Canada; London, 493–500.
16. 16 Rudenko, L, Isakova-Sivak, I, Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus. Expert Rev Vaccines 14 (2015), 395–412.
17. 17 Lewis K, Rahman MZ, Levine M, et al. Immunogenicity and viral shedding of a seasonal trivalent live attenuated influenza virus vaccine among children in Bangladesh. Macrae Foundation's XVII International Symposium on Respiratory Viral Infections. March 8, 2015; Vancouver, BC, Canada.
18. 18 Ilyushina, NA, Haynes, BC, Hoen, AG, et al. Live attenuated and inactivated influenza vaccines in children. J Infect Dis 211 (2015), 352–360.
19. 19 Edwards, KM, King, JC, Steinhoff, MC, et al. Safety and immunogenicity of live attenuated cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in infants and children. J Infect Dis 163 (1991), 740–745.
20. 20 Keitel, WA, Couch, RB, Quarles, JM, Cate, TR, Baxter, B, Maassab, HF, Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. J Infect Dis 167 (1993), 305–311.
21. 21 Keitel, W, Neuzil, K, Treanor, J, Immunogenicity and efficacy of inactivated/live virus seasonal and pandemic vaccines. Wester, R, Monto, A, Braciale, T, Lamb, R, (eds.) Textbook of Influenza, 2nd edn., 2013, Wiley Blackwell, Hoboken.
22. 22 Plotkin, SA, Correlates of protection induced by vaccination. Clin Vaccine Immunol 17 (2010), 1055–1065.
23. 23 Forrest, BD, Pride, MW, Dunning, AJ, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 15 (2008), 1042–1053.
24. 24 Wright, PF, Hoen, AG, Ilyushina, NA, et al. Correlates of immunity to influenza as determined by challenge of children with live, attenuated influenza vaccine. Open Forum Infect Dis, 3, 2016, ofw108.
25. 25 Grohskopf, LA, Sokolow, LZ, Olsen, SJ, Bresee, JS, Broder, KR, Karron, RA, Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015–16 Influenza Season. MMWR Morb Mortal Wkly Rep 64 (2015), 818–825.
26. 26 Bracco, NH, Farhat, CK, Tregnaghi, MW, et al. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J 28 (2009), 365–371.
27. 27 Tam, JS, Capeding, MR, Lum, LC, et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 26 (2007), 619–628.
28. 28 Kulkarni, PS, Agarkhedkar, S, Lalwani, S, et al. Effectiveness of an Indian-made attenuated influenza A(H1N1)pdm 2009 vaccine: a case control study. Hum Vaccin Immunother 10 (2014), 566–571.
29. 29 US Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP): Summary Report, 2015. Published online Feb 26. http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2015-02.pdf (accessed July 18, 2016).
30. 30 Cotter, CR, Jin, H, Chen, Z, A single amino acid in the stalk region of the H1N1pdm influenza virus HA protein affects viral fusion, stability and infectivity. PLoS Pathog, 10, 2014, e1003831.
31. 31 US Centers for Disease Control and Prevention. Weekly US Influenza Surveillance Report. http://www.cdc.gov/flu/weekly/, 2016 (accessed July 18, 2016).
32. 32 US Centers for Disease Control and Prevention; ACIP votes down use of LAIV for 2016–2017 flu season. http://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html, 2016 (accessed July 18, 2016).
33. 33 US Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices (ACIP): Summary Report. https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html, 2016 (accessed Sept 29, 2016).
34. 34 Skowronski, DM, Chambers, C, Sabaiduc, S, et al. Integrated sentinel surveillance linking genetic, antigenic, and epidemiologic monitoring of influenza vaccine-virus relatedness and effectiveness during the 2013–2014 influenza season. J Infect Dis 212 (2015), 726–739.
35. 35 Ortiz, JR, Goswami, D, Lewis, KD, et al. Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh. Vaccine 33 (2015), 3415–3421.
36. 36 MedImmune. Flumist Quadrivalent package insert. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm294307.pdf, 2016 (accessed July 18, 2016).
37. 37 Victor JC, Diallo A, Niang MN, et al. Effectiveness of seasonal influenza vaccination of children in tropical developing Africa: a cluster-randomized trial. Options for the Control of Influenza VIII; Cape Town, South Africa; Sept 6, 2013.
38. 38 Niang, MN, Diop, OM, Sarr, FD, et al. Viral etiology of respiratory infections in children under 5 years old living in tropical rural areas of Senegal: The EVIRA project. J Med Virol 82 (2010), 866–872.
39. 39 Dosseh, A, Rogier, C, Influenza survey in Senegal. Trans R Soc Trop Med Hyg, 90, 1996, 377.